Cargando…
CD1C is associated with breast cancer prognosis and immune infiltrates
BACKGROUND: The tumor microenvironment (TME) in breast cancer plays a vital role in occurrence, development, and therapeutic responses. However, immune and stroma constituents in the TME are major obstacles to understanding and treating breast cancer. We evaluated the significance of TME-related gen...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9905770/ https://www.ncbi.nlm.nih.gov/pubmed/36755259 http://dx.doi.org/10.1186/s12885-023-10558-2 |
_version_ | 1784883872290308096 |
---|---|
author | Chen, Xiao Zhang, Jianzhong Lei, Xinhan Yang, Lei Li, Wanwan Zheng, Lu Zhang, Shuai Ding, Yihan Shi, Jianing Zhang, Lei Li, Jia Tang, Tong Jia, WenJun |
author_facet | Chen, Xiao Zhang, Jianzhong Lei, Xinhan Yang, Lei Li, Wanwan Zheng, Lu Zhang, Shuai Ding, Yihan Shi, Jianing Zhang, Lei Li, Jia Tang, Tong Jia, WenJun |
author_sort | Chen, Xiao |
collection | PubMed |
description | BACKGROUND: The tumor microenvironment (TME) in breast cancer plays a vital role in occurrence, development, and therapeutic responses. However, immune and stroma constituents in the TME are major obstacles to understanding and treating breast cancer. We evaluated the significance of TME-related genes in breast cancer. METHODS: Invasive breast cancer (BRCA) samples were retrieved from the TCGA and GEO databases. Stroma and immune scores of samples as well as the proportion of tumor infiltrating immune cells (TICs) were calculated using the ESTIMATE and CIBERSORT algorithms. TME-related differentially expressed genes (DEGs) were analyzed by a protein interaction (PPI) network and univariate Cox regression to determine CD1C as a hub gene. Subsequently, the prognostic value of CD1C, its response to immunotherapy, and its mechanism in the TME were further studied. RESULTS: In BRCA, DEGs were determined to identify CD1C as a hub gene. The expression level of CD1C in BRCA patients was verified based on the TCGA database, polymerase chain reaction (PCR) results, and western blot analysis. Immunohistochemical staining (IHC) results revealed a correlation between prognosis, clinical features, and CD1C expression in BRCA. Enrichment analysis of GSEA and GSVA showed that CD1C participates in immune-associated signaling pathways. CIBERSORT showed that CD1C levels were associated with tumor immune infiltrating cells (TILs), such as different kinds of T cells. Gene co-expression analysis showed that CD1C and the majority of immune-associated genes were co-expressed in BRCA. In renal cell carcinoma, patients with a high expression of CD1C had a better immunotherapy effect. CONCLUSION: CD1C is an important part of the TME and participates in immune activity regulation in breast tumors. CD1C is expected to become a prognostic marker and a new treatment target for breast cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-10558-2. |
format | Online Article Text |
id | pubmed-9905770 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-99057702023-02-08 CD1C is associated with breast cancer prognosis and immune infiltrates Chen, Xiao Zhang, Jianzhong Lei, Xinhan Yang, Lei Li, Wanwan Zheng, Lu Zhang, Shuai Ding, Yihan Shi, Jianing Zhang, Lei Li, Jia Tang, Tong Jia, WenJun BMC Cancer Research BACKGROUND: The tumor microenvironment (TME) in breast cancer plays a vital role in occurrence, development, and therapeutic responses. However, immune and stroma constituents in the TME are major obstacles to understanding and treating breast cancer. We evaluated the significance of TME-related genes in breast cancer. METHODS: Invasive breast cancer (BRCA) samples were retrieved from the TCGA and GEO databases. Stroma and immune scores of samples as well as the proportion of tumor infiltrating immune cells (TICs) were calculated using the ESTIMATE and CIBERSORT algorithms. TME-related differentially expressed genes (DEGs) were analyzed by a protein interaction (PPI) network and univariate Cox regression to determine CD1C as a hub gene. Subsequently, the prognostic value of CD1C, its response to immunotherapy, and its mechanism in the TME were further studied. RESULTS: In BRCA, DEGs were determined to identify CD1C as a hub gene. The expression level of CD1C in BRCA patients was verified based on the TCGA database, polymerase chain reaction (PCR) results, and western blot analysis. Immunohistochemical staining (IHC) results revealed a correlation between prognosis, clinical features, and CD1C expression in BRCA. Enrichment analysis of GSEA and GSVA showed that CD1C participates in immune-associated signaling pathways. CIBERSORT showed that CD1C levels were associated with tumor immune infiltrating cells (TILs), such as different kinds of T cells. Gene co-expression analysis showed that CD1C and the majority of immune-associated genes were co-expressed in BRCA. In renal cell carcinoma, patients with a high expression of CD1C had a better immunotherapy effect. CONCLUSION: CD1C is an important part of the TME and participates in immune activity regulation in breast tumors. CD1C is expected to become a prognostic marker and a new treatment target for breast cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-10558-2. BioMed Central 2023-02-08 /pmc/articles/PMC9905770/ /pubmed/36755259 http://dx.doi.org/10.1186/s12885-023-10558-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Chen, Xiao Zhang, Jianzhong Lei, Xinhan Yang, Lei Li, Wanwan Zheng, Lu Zhang, Shuai Ding, Yihan Shi, Jianing Zhang, Lei Li, Jia Tang, Tong Jia, WenJun CD1C is associated with breast cancer prognosis and immune infiltrates |
title | CD1C is associated with breast cancer prognosis and immune infiltrates |
title_full | CD1C is associated with breast cancer prognosis and immune infiltrates |
title_fullStr | CD1C is associated with breast cancer prognosis and immune infiltrates |
title_full_unstemmed | CD1C is associated with breast cancer prognosis and immune infiltrates |
title_short | CD1C is associated with breast cancer prognosis and immune infiltrates |
title_sort | cd1c is associated with breast cancer prognosis and immune infiltrates |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9905770/ https://www.ncbi.nlm.nih.gov/pubmed/36755259 http://dx.doi.org/10.1186/s12885-023-10558-2 |
work_keys_str_mv | AT chenxiao cd1cisassociatedwithbreastcancerprognosisandimmuneinfiltrates AT zhangjianzhong cd1cisassociatedwithbreastcancerprognosisandimmuneinfiltrates AT leixinhan cd1cisassociatedwithbreastcancerprognosisandimmuneinfiltrates AT yanglei cd1cisassociatedwithbreastcancerprognosisandimmuneinfiltrates AT liwanwan cd1cisassociatedwithbreastcancerprognosisandimmuneinfiltrates AT zhenglu cd1cisassociatedwithbreastcancerprognosisandimmuneinfiltrates AT zhangshuai cd1cisassociatedwithbreastcancerprognosisandimmuneinfiltrates AT dingyihan cd1cisassociatedwithbreastcancerprognosisandimmuneinfiltrates AT shijianing cd1cisassociatedwithbreastcancerprognosisandimmuneinfiltrates AT zhanglei cd1cisassociatedwithbreastcancerprognosisandimmuneinfiltrates AT lijia cd1cisassociatedwithbreastcancerprognosisandimmuneinfiltrates AT tangtong cd1cisassociatedwithbreastcancerprognosisandimmuneinfiltrates AT jiawenjun cd1cisassociatedwithbreastcancerprognosisandimmuneinfiltrates |